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Aims The optimal platelet inhibition strategy for ACS patients managed without revascularization is unknown.
We aimed to evaluate efficacy and safetyof ticagrelor vs. clopidogrel in the non-ST-elevation acute coronary syndrome
(NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascu-
larization within 10 days of randomization.
Methods
and results
We performed a retrospective analysis of the primary endpoint of cardiovascular death/myocardial infarction/stroke.
Among 18 624 PLATO patients, 11 080 (59%) were categorized as NSTE-ACS at randomization. During the initial 10
days, 74% had angiography, 46% PCI, and 5% CABG. In NSTE-ACS patients, the primary endpoint was reduced with tica-
grelor vs. clopidogrel [10.0 vs. 12.3%; hazard ratio (HR) 0.83; 95% confidence interval (CI) ¼ 0.74–0.93], as was myocar-
dial infarction (6.6 vs. 7.7%; HR 0.86; 95% CI ¼ 0.74–0.99), cardiovascular death (3.7 vs. 4.9%; HR 0.77; 95% CI ¼ 0.64–
0.93), andall-causedeath (4.3 vs. 5.8%;HR0.76; 95%CI ¼ 0.64–0.90).Majorbleeding ratewas similarbetweentreatment
groups (13.4 vs. 12.6%; HR1.07; 95% CI ¼ 0.95–1.19), but ticagrelorwas associated with an increase in non-CABG major
bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI ¼ 1.05–1.56). Within the first 10 days, 5366 (48.4%) patients were managed
without revascularization. Regardless of revascularization or not, ticagrelor consistently reduced the primary
outcome (HR 0.86 vs. 0.85, interaction P ¼ 0.93), and all-cause death (HR 0.75 vs. 0.73, interaction P ¼ 0.89) with no
significant increase in overall major bleeding.
Conclusion In patients with NSTE-ACS, benefit of ticagrelor over clopidogrel in reducing ischaemic events and total mortality was
consistent with the overall PLATO trial, independent of actually performed revascularization during the initial 10 days.
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Introduction
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is stand-
ard of care in acute coronary syndromes (ACS).1,2 Ticagrelor is the
first reversibly binding direct P2Y12 inhibitor. As opposed to clopi-
dogrel and prasugrel, it does not require enzymatic activation, and
causes faster, greater, and more consistent platelet inhibition
compared with clopidogrel.3,4 The Platelet Inhibition and Patient
Outcomes (PLATO) trial compared ticagrelor with clopidogrel in
patients with ACS. Ticagrelor was superior in preventing ischaemic
events (the composite of death from vascular causes, myocardial
infarction, and stroke), as well as death from any cause, without
a significant increase in all-cause major bleeding. PLATO inclu-
ded both invasively and non-invasively managed patients. The deci-
sion on which management strategy to pursue was made by the
investigator.5
The third-generation thienopyridine prasugrel is, like clopidogrel,
an irreversible P2Y12 inhibitor, but with faster and more consistent
platelet inhibition.6 Prasugrel, when compared with clopidogrel,
reduced ischaemic events in patients with ACS planned for PCI in
the Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel (TRITON),7 but in non-
ST-elevation acute coronary syndrome (NSTE-ACS) patients plan-
ned for management without revascularization, prasugrel showed
no benefit over clopidogrel in the Targeted Platelet Inhibition to
Clarify the Optimal Strategy to Medically Manage Acute Coronary
Syndromes (TRILOGY-ACS) trial.8
The aim of the present study was to explore the effect of
ticagrelor vs. clopidogrel in the total NSTE-ACS subgroup of the
PLATO trial and also stratified by initial management with or
without revascularization.
Methods
Study design
The PLATO trial (ClinicalTrials.gov No. NCT00391872) was an inter-
national randomized double-blind, double-dummy phase III study com-
paring ticagrelor with clopidogrel in ACS. Details of the study design
and overall results have been published previously.5,9 Briefly, a total of
18 624 patients were randomized to receive either ticagrelor or clopido-
grel on background treatment with aspirin. The study included patients
with ST-elevation MI intended for primary PCI, as well as patients with
non-ST-elevation ACS, regardless if aimed for an initial invasive or non-
invasive treatment strategy. It adhered to the Declaration of Helsinki,
to the specifications of the International Conference of Harmonization,
and to Good Clinical Practice; and was approved by national and institu-
tional regulatory authorities and ethics committees. All participants pro-
vided written informed consent.
Patients
Two or more of the following inclusion criteria were required for
patients enrolled without ST-elevation ACS at admission: (1)
ST-segment changes on ECG indicating ischaemia [ST-segment depres-
sion or transient elevation (≥1 mm) in at least two contiguous leads];
(2) positive biomarker indicating myocardial necrosis (troponin I or T
or CK-MB above the upper limit of normal); (3) one of the following:
≥60 years of age, previous myocardial infarction or coronary artery
bypass surgery, coronary artery disease with ≥50% stenosis in ≥2
vessels, previous ischaemic stroke, transient ischaemic attack (TIA),
carotid stenosis, cerebral revascularization, diabetes mellitus, peripheral
artery disease, or chronic renal dysfunction.
In the current analysis, NSTE-ACS was in the data-base defined as
absence of either persistent ST-segment elevation of 1 mV for 20 min
in two contiguous leads or new (or presumed new) left bundle branch
block in entry ECG. In addition to the overall NSTE-ACS population,
we also analysed outcomes in the subgroups of NSTE-ACS patients
who initially underwent revascularization and those who were treated
without early revascularization. Both cohorts required endpoint-free
survival for 10 days post-randomization to determine revascularization
status. The no-revascularization subgroup was defined as NSTE-ACS
patients who did not undergo any revascularization procedure (PCI or
CABG) with or without angiography during the first 10 days.
Endpoints
The primary efficacy endpoint of the present study was the composite of
cardiovascular death, myocardial infarction, (excluding silent infarc-
tions) and stroke. Each component alone and all-cause death were
secondary efficacy endpoints. Major bleeding by PLATO criteria9 and
life-threatening/fatal bleeding were the primary safety endpoints.
Secondary safety endpoints were CABG-related major bleeding,
non-CABG-related major bleeding, minor bleeding, intracranial bleed-
ing, and fatal bleeding. Additional secondary safety outcomes were
bleeding events as defined by TIMI (major, minor, and non-CABG
related major) and GUSTO (severe and moderate). An independent
central adjudication committee, unaware of treatment assignments,
assessed all endpoints. Major bleeding as defined by TIMI was recorded
from the electronic case report form, where a drop of 50 g/L in haemo-
globin was used as a cut-off, but this did not necessarily require clinical
evidence of bleeding.
Statistical analyses
Patient characteristics and medical history, in-hospital procedures and
medications, discharge ACS status, and post-discharge medications are
presented by treatment in the NSTE-ACS patient cohort as well as by
revascularization status subgroup. Continuous variables are presented
as median and 25th–75th percentiles; categorical variables are pre-
sented as number and percentage. The treatment effect of ticagrelor
vs. clopidogrel on the primary and secondary endpoints was compared
within the subgroup of NSTE-ACS patients. Kaplan–Meier estimated
event rates at 360 days and total number of observed events during
the study were presented for each endpoint. Hazard ratios (HR), con-
fidence intervals (CI), and P-values from unadjusted Cox proportional
hazards regression models were presented. Kaplan–Meier estimated
event rates were plotted by treatment for the primary efficacy end-
point, all-cause death, major bleeding, and non-CABG related major
bleeding.
To examine whether the effect of ticagrelor in patients with
NSTE-ACS differed based on early revascularization, Cox proportional
hazards models were fitted for each endpoint using a treatment-
by-revascularization interaction term. In these models, we adjusted for
region of the world to account for differences in revascularization prac-
tice and the time-to-event was measured from a landmark at 10 days
post-randomization. Kaplan–Meier rates 350 days post-landmark are
presented for each treatment/revascularization category along with HR
for ticagrelor vs. clopidogrel in the revascularization and medical manage-
ment subgroups. Interaction P-values assess whether the treatment
effect is different depending on revascularization status. Kaplan–Meier
event rates adjusted for region are plotted by the four treatment/
revascularization categories for the primary efficacy endpoint, all-cause
death, major bleeding, and non-CABG related major bleeding. For con-
sistencywith the PLATOdesign paper,9 wealso performed a 30-day land-
mark analysis; and as a sensitivity analysis, we also performed a 10-day
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landmark analysis of the full study population. Finally, the association of
treatment with the primary efficacy endpoint was evaluated within
several patient cohorts using Cox proportional hazards models, separ-
ately within the revascularization and non-revascularization subgroups.
Forest plots present the HR for ticagrelor vs. clopidogrel in each sub-
group cohort. Endpoints are defined using intent to treat and a P-value
of 0.05 is used to denote statistical significance. Data were analysed
using SAS version 9.2 for all analyses.
Results
Patient characteristics
The PLATO trial included 18 624 patients with ACS, of which 11 080
patientswereclassifiedasNSTE-ACSat randomization.Of these,5581
were randomized to ticagrelor and 5499 to clopidogrel (Figure 1). The
baseline and in-hospital characteristics were similar between groups in
the overall NSTE-ACS population (Table 1). In the overall NSTE-ACS
group, 74% of patients had a coronary angiography performed, 46%
underwent PCI, and 5% CABG. The discharge diagnosis (in this popu-
lation categorized as NSTE-ACS at admission) was NSTEMI in 65%,
STEMI in 8%, and unstable angina/other in 27%.
At 10 days post-randomization, 5366 patients were alive and had
not undergone revascularization. There were regional differences
in the proportion of patients undergoing revascularization during
the initial 10 days (Asia/Australia 44%, Central/South America
40.3%, Europe/Middle East/Africa 49.8%, North America 71.6%).
Non-revascularized and revascularized patients were of similar age
(63 vs. 65), but patients who did not undergo revascularization
were more likely to be of female gender (39 vs. 25%), and more
likely to have comorbidities (e.g. previous myocardial infarction,
heart failure, renal disease). Although non-revascularized patients
had morecomorbidities, theywere less likely tobe troponin I positive
(Table 1). The proportion of patients with TIMI risk score .2 was
slightly higher in the revascularization group (92 vs. 88%). During
the first 10 days, 47% of non-revascularized patients underwent cor-
onary angiography. When including only those who had angiography
during the initial 10 days, female gender was more common in the
non-revascularized (36%) than revascularized (25%). No significant
coronary artery disease at angiography was noted in 32 and 0.7% of
the non-revascularized and revascularized, respectively.
Efficacy in the overall non-ST-elevation
acute coronary syndrome population
Efficacy and safetyoutcomes of the overall NSTE-ACSpopulation are
summarized in Table 2, and Kaplan–Meier curves are shown in
Supplementary material online. The incidence of the primary
composite endpoint was reduced with ticagrelor vs. clopidogrel
(10.0 vs. 12.3%; HR 0.83; 95% CI ¼ 0.74–0.93; P ¼ 0.0013) (see
Supplementary material online, Figure S1A). Cardiovascular death
occurred less often in the ticagrelor group than in the clopidogrel
group (3.7 vs. 4.9%; HR 0.77; 95% CI ¼ 0.64–0.93; P ¼ 0.0070),
and myocardial infarction was also less common with ticagrelor
vs. clopidogrel (6.6 vs. 7.7%; HR 0.86; 95% CI ¼ 0.74–0.99;
P ¼ 0.0419), whereas stroke incidence did not differ significantly
between treatment arms (1.3 vs. 1.4%; HR 0.95; 95% CI 0.69–1.33;
P ¼ 0.79). All-cause death was reduced in those treated with
Figure 1 Trial profile—patients classified by entry ECG and by treatment during the first 10 days after randomization.
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Table1 Baseline characteristics and invasiveprocedures by randomized treatment in theoverallNSTE-ACSpopulation,
and by initial treatment strategy (within the first 10 days after randomization)
Overall NSTE-ACS NSTE-ACS with
revascularization
NSTE-ACS without
revascularization
Ticagrelor
(N5 5581)
Clopidogrel
(N5 5499)
Ticagrelor
(N 5 2873)
Clopidogrel
(N 5 2841)
Ticagrelor
(N 5 2708)
Clopidogrel
(N 5 2658)
Demographics
Age, median (25th–75th
percentile), years
64 (56–72) 64 (56–72) 63 (55–71) 63 (55–71) 65 (57–73) 65 (57–73)
Age ≥ 75 years, n (%) 955 (17.1) 1024 (18.6) 420 (14.6) 460 (16.2) 535 (19.8) 564 (21.2)
Female gender, n (%) 1746 (31.3) 1746 (31.8) 706 (24.6) 716 (25.2) 1040 (38.4) 1030 (38.8)
Body weight ,60 kg, n (%) 398 (7.2) 389 (7.1) 165 (5.8) 172 (6.1) 233 (8.6) 217 (8.2)
Body mass index, median
(25th–75th percentile),
kg/m2
27.5 (24.8–30.8) 27.4 (24.8–30.5) 27.5 (24.9–30.8) 27.5 (24.9–30.5) 27.5 (24.7–30.6) 27.3 (24.6–30.5)
GRACE risk scorenomogram 130 (112–150) 130 (112–149) 128 (110–145) 127 (110–145) 133 (114–154) 134 (116–153)
Cardiovascular risk factors, n (%)
Current smoking 1636 (29.4) 1640 (29.9) 1000 (34.8) 960 (33.8) 636 (23.6) 680 (25.6)
Hypertension 3915 (70.2) 3835 (69.8) 1881 (65.5) 1886 (66.4) 2034 (75.3) 1949 (73.4)
Dyslipidaemia 2885 (51.8) 2852 (51.9) 1515 (52.8) 1569 (55.2) 1370 (50.7) 1283 (48.3)
Diabetes mellitus 1608 (28.9) 1520 (27.7) 756 (26.3) 747 (26.3) 852 (31.6) 773 (29.1)
Medical history, n (%)
Angina pectoris 2932 (52.6) 2890 (52.6) 1337 (46.5) 1356 (47.7) 1595 (59.1) 1534 (57.8)
Myocardial infarction 1400 (25.1) 1410 (25.7) 609 (21.2) 608 (21.4) 791 (29.3) 802 (30.2)
Congestive heart failure 397 (7.1) 429 (7.8) 99 (3.4) 103 (3.6) 298 (11.0) 326 (12.3)
Percutaneous coronary
intervention (PCI)
944 (16.9) 918 (16.7) 537 (18.7) 517 (18.2) 407 (15.1) 401 (15.1)
Coronary artery bypass graft
(CABG)
434 (7.8) 474 (8.6) 214 (7.4) 218 (7.7) 220 (8.1) 256 (9.6)
Transient ischaemic attack 185 (3.3) 189 (3.4) 82 (2.9) 74 (2.6) 103 (3.8) 115 (4.3)
Non-hemorrhagic stroke 246 (4.4) 243 (4.4) 81 (2.8) 98 (3.5) 165 (6.1) 145 (5.5)
Peripheral arterial disease 400 (7.2) 413 (7.5) 174 (6.1) 204 (7.2) 226 (8.4) 209 (7.9)
Chronic renal disease 273 (4.9) 279 (5.1) 117 (4.1) 108 (3.8) 156 (5.8) 171 (6.4)
Physical findings, median (25th–75th percentile)
Heart rate (bpm) 72 (64–80) 72 (64–81) 71 (62–80) 72 (63–80) 72 (64–82) 72 (64–82)
Systolic blood pressure
(mmHg)
135 (120–150) 134 (120–150) 135 (120–150) 135 (120–150) 134 (120–150) 132 (120–150)
Diastolic blood pressure
(mmHg)
80 (70–89) 80 (70–87) 80 (70–89) 80 (70–87) 80 (70–89) 80 (70–87)
Risk indicators, n (%)
Troponin positive, n (%) 4356 (80.8) 4323 (81.3) 2522 (89.6) 2486 (89.3) 1834 (71.3) 1837 (72.4)
ST depression (≥1 mm) 3158 (56.8) 3201 (58.4) 1547 (54.0) 1535 (54.2) 1611 (59.8) 1666 (62.8)
TIMI risk score . 2 4838 (89.7) 4785 (89.8) 2584 (91.3) 2566 (91.8) 2254 (88.0) 2219 (87.7)
Type of ACS at discharge, n (%)
STEMI 449 (8.1) 437 (8.0) 330 (11.5) 305 (10.7) 119 (4.4) 132 (5.0)
NSTEMI 3605 (64.8) 3525 (64.3) 2045 (71.2) 2025 (71.3) 1560 (58.0) 1500 (56.7)
UA/other 1509 (27.1) 1524 (27.8) 497 (17.3) 510 (18.0) 1012 (37.6) 1014 (38.3)
Antithrombotic treatment during index hospitalization, n (%)
Aspirin 5386 (96.6) 5316 (96.8) 2797 (97.4) 2779 (97.8) 2589 (95.9) 2537 (95.8)
Unfractionated heparin 2910 (52.1) 2856 (51.9) 1845 (64.2) 1845 (64.9) 1065 (39.3) 1011 (38.0)
Continued
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ticagrelor vs. clopidogrel (4.3 vs. 5.8%; HR 0.76; 95% CI ¼ 0.64–0.90;
P ¼ 0.0020) (see Supplementary material online, Figure S1B).
Safety
With ticagrelor when compared with clopidogrel, there was no sig-
nificant difference in PLATO major bleeding (13.4 vs. 12.6%; HR 1.07;
95% CI¼ 0.95–1.19; P ¼ 0.26), but a higher rate of non-CABG-
related major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI ¼ 1.05–1.56;
P ¼ 0.0139) (see Supplementary material online, Figure S2A and B).
There was no significant difference in the rate of life-threatening or
fatal bleeding (6.6 vs. 6.5%; HR 1.05; 95% CI ¼ 0.90–1.22, P ¼ 0.56),
noranysignificantdifference in therateof intracranialbleedingwith tica-
grelor compared with clopidogrel (0.3 vs. 0.2%; HR 2.01; 95% CI ¼
0.81–4.99; P ¼ 0.13). The composite of major or minor bleeding (by
PLATO criteria) occurred more often in the ticagrelor group (18.2
vs. 16.3%; HR 1.14; 95% CI¼ 1.03–1.25, P ¼ 0.0078). When assessed
by TIMI criteria, there was no significant difference in major or minor
bleeding (13.2 vs. 12.3%; HR 1.08; 95% CI ¼ 0.97–1.21; P ¼ 0.16).
TIMI major bleeding, GUSTO severe, and GUSTO moderate or
severe bleeding also did not appear to differ significantly between tica-
grelor and clopidogrel, whereas TIMI non-CABG-related major bleed-
ing was more common in the ticagrelor group (Table 2).
Efficacy and safety according to treatment
strategy
Event rates were considerably higher in NSTE-ACS patients treated
without revascularization compared with patients undergoing
revascularization during the initial 10 days. For both revascularized
and non-revascularized patients, there were similar proportional
reductions of the primary endpoint with ticagrelor compared with
clopidogrel (HR 0.86 vs. 0.85, interaction P ¼ 0.93) (Figure 2A,
Table 3) consistent with the overall trial. There was also a consistent
reduction in all-cause death (HR 0.75 vs. 0.73; interaction P ¼ 0.89)
(Figure 2B). No significant difference in overall major bleeding was
seen with ticagrelor vs. clopidogrel within each treatment strategy
(revascularization/no revascularization) (Figure 3A). There was a
higher incidence of non-CABG-related major bleeding with ticagre-
lor vs. clopidogrel in patients with NSTE-ACS with no significant
interaction by invasive treatment strategy (HR 1.32 vs. 1.07; inter-
action P ¼ 0.43) (Figure 3B). The primary outcome was reduced in
major subgroups in both revascularized and non-revascularized
patients (see Supplementary material online, Figures S3 and S4).
The results were consistent with a 30-day landmark for revasculari-
zation (see Supplementary material online, Table S1), as well as in
the full study population (see Supplementary material online,
Table S2). In patients who underwent angiography during the initial
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Table 1 Continued
Overall NSTE-ACS NSTE-ACS with
revascularization
NSTE-ACS without
revascularization
Ticagrelor
(N 5 5581)
Clopidogrel
(N 5 5499)
Ticagrelor
(N 5 2873)
Clopidogrel
(N5 2841)
Ticagrelor
(N 5 2708)
Clopidogrel
(N 5 2658)
Low molecular weight
heparin
3181 (57.0) 3084 (56.1) 1568 (54.6) 1501 (52.8) 1613 (59.6) 1583 (59.6)
Fondaparinux 194 (3.5) 191 (3.5) 87 (3.0) 76 (2.7) 107 (4.0) 115 (4.3)
Bivalirudin 140 (2.5) 133 (2.4) 135 (4.7) 122 (4.3) 5 (0.2) 11 (0.4)
GP IIb/IIIa inhibitor 1170 (21.0) 1117 (20.3) 982 (34.2) 963 (33.9) 188 (6.9) 154 (5.8)
Other drug from randomization to end of study, n (%)
Beta-blocker 4768 (85.4) 4685 (85.2) 2536 (88.3) 2512 (88.4) 2232 (82.4) 2173 (81.8)
ACE-inhibitor and/or ARB 4693 (84.2) 4602 (83.8) 2447 (85.2) 2433 (85.6) 2246 (83.2) 2169 (81.9)
Statin 5196 (93.1) 5109 (92.9) 2777 (96.7) 2745 (96.6) 2419 (89.3) 2364 (88.9)
Proton-pump inhibitor 2776 (49.7) 2613 (47.5) 1618 (56.3) 1536 (54.1) 1158 (42.8) 1077 (40.5)
Calcium channel inhibitor 1553 (27.8) 1515 (27.6) 720 (25.1) 723 (25.4) 833 (30.8) 792 (29.8)
Diuretic 2393 (42.9) 2280 (41.5) 1073 (37.3) 1037 (36.5) 1320 (48.9) 1243 (46.9)
Invasive procedures
Coronary angiography
During first 10 days, n (%) 4143 (74.5) 4072 (74.2) 2873 (100.0) 2841 (100.0) 1270 (47.2) 1231 (46.6)
After first 10 days, n (%) 357 (6.4) 335 (6.1) 0 (0) 0 (0) 357 (13.3) 335 (12.7)
PCI
During first 10 days, n (%) 2590 (46.4) 2550 (46.4) 2590 (90.1) 2550 (89.8) 0 (0) 0 (0)
After first 10 days, n (%) 279 (5.0) 291 (5.3) 11 (0.4) 3 (0.1) 268 (9.9) 288 (10.8)
CABG
During first 10 days, n (%) 296 (5.3) 305 (5.5) 296 (10.3) 305 (10.7) 0 (0) 0 (0)
After first 10 days, n (%) 382 (6.8) 375 (6.8) 55 (1.9) 55 (1.9) 327 (12.1) 320 (12.0)
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10 days with or without significant coronary disease, the effect of tica-
grelor vs. clopidogrel was consistent (see Supplementary material
online, Table S3).
Discussion
In this subgroup analysis, ticagrelor compared with clopidogrel
reduced the composite endpoint of cardiovascular death, myocardial
infarction, and stroke as well as the individual endpoints of cardiovas-
cular death, myocardial infarction, and all-cause death without any
significant difference in major bleeding in patients with an entry diag-
nosis of NSTE-ACS. The event curves for the primary composite
endpoint and total mortality separated continuously for the duration
of the trial. The benefits with ticagrelor were observed both in
patients who underwent and in those who did not undergo early
revascularization, regardless whether angiography was performed
or not. These results areconsistent with the previously reported sub-
group analysis of all ACS patients with an intended strategy (prior to
randomization) of no revascularization, where about one-fifth still
underwent PCI and about 4% had CABG surgery before discharge.10
Although current guidelines advocate early invasive management
in NSTE-ACS,1,2 a large proportion of patients are managed non-
invasively.11,12 Patients who are managed without revascularization
usually have more comorbidities, higher risk of bleeding, and inferior
outcome than patients who are revascularized.13 The optimal plate-
let inhibition strategy in these patients has been uncertain. P2Y12 in-
hibition has previously been shown to reduce ischaemic events in
NSTE-ACS patients managed without revascularization. In the Clopi-
dogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial,
which randomized NSTE-ACS patients to receive either clopidogrel
or placebo (on background aspirin treatment), 64% of patients did
not undergo revascularization after randomization. There were
almost identical relative reductions in CV death/MI/stroke with
clopidogrel in the non-invasive and invasive subgroups.14 The Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trial studied the addition
of clopidogrel to aspirin in a stable, more heterogeneous population
at risk for atherothrombotic events. Overall, the combination was
not more effective than aspirin monotherapy, but a trend towards
benefit was noted in thosewith symptomatic atherosclerotic disease,
whereas a trend towards harm was seen in those included based only
on multiple cardiovascular risk factors.15
This issue was also recently studied in the TRILOGY-ACS trial, in
which NSTE-ACS patients intended for management without revas-
cularization were prospectively randomized to receive either prasu-
grel or clopidogrel (both irreversible P2Y12 inhibitors). The results
showed no significant overall benefit of prasugrel over clopidogrel
during 24 months, even though the Kaplan–Meier curves for the ef-
ficacy endpoints tended to separate after 1 year,8 and with a
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Table 2 Efficacy and safety outcomes in patients with NSTE-ACS
Ticagrelor % (n) Clopidogrel % (n) HR (95% CI) P-value
Efficacy endpoints
CV death/MI (excluding silent)/stroke 10.0 (533) 12.3 (630) 0.83 (0.74, 0.93) 0.0013
All-cause death/MI(excl. silent)/stroke 10.5 (557) 13.0 (664) 0.82 (0.73, 0.92) 0.0006
CV death/MI(all)/stroke/severe recurrent ischaemia/recurrent
ischaemia/TIA/arterial thrombotic event
15.5 (824) 17.8 (918) 0.88 (0.80, 0.96) 0.0058
Myocardial infarction (excluding silent) 6.6 (345) 7.7 (392) 0.86 (0.74, 0.99) 0.0419
Cardiovascular death (includes vascular and unknown deaths) 3.7 (194) 4.9 (247) 0.77 (0.64, 0.93) 0.0070
Stroke 1.3 (69) 1.4 (71) 0.95 (0.69, 1.33) 0.79
All-cause death 4.3 (224) 5.8 (290) 0.76 (0.64, 0.90) 0.0020
Safety endpoints
Major bleeding (study criteria) 13.4 (660) 12.6 (618) 1.07 (0.95, 1.19) 0.26
Major or minor bleeding (study criteria) 18.2 (900) 16.3 (794) 1.14 (1.03, 1.25) 0.0078
Non-CABG related major bleeding (study criteria) 4.8 (225) 3.8 (176) 1.28 (1.05, 1.56) 0.0139
Fatal bleeding 0.3 (13) 0.4 (18) 0.72 (0.35, 1.47) 0.37
Life threatening or fatal bleeding (study criteria) 6.6 (331) 6.5 (315) 1.05 (0.90, 1.22) 0.56
Intracranial bleeding 0.3 (14) 0.2 (7) 2.01 (0.81, 4.99) 0.13
Other major bleeding 7.2 (344) 6.6 (318) 1.08 (0.93, 1.25) 0.34
Major bleeding (TIMI criteria) 9.2 (452) 8.7 (422) 1.07 (0.94, 1.22) 0.33
Major or minor bleeding (TIMI criteria) 13.2 (653) 12.3 (602) 1.08 (0.97, 1.21) 0.16
Non-CABG related major bleeding (TIMI criteria) 2.9 (137) 2.2 (99) 1.39 (1.07, 1.80) 0.0131
GUSTO severe bleeding 3.1 (146) 3.2 (151) 0.96 (0.77, 1.21) 0.74
GUSTO moderate or severe bleeding 8.6 (416) 7.8 (382) 1.08 (0.94, 1.25) 0.25
Each treatment group is summarized as Kaplan–Meier rates at 360 days and total number of events during the study. P-values and hazard ratios (95% CI) come from unadjusted Cox
models testing ticagrelor vs. clopidogrel.
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reduction of the primary outcome in the subgroup who underwent
angiography.16 In the no revascularization subgroup of the current
PLATO NSTE-ACS substudy, there were consistent benefits with
ticagrelor when compared with clopidogrel concerning both mortal-
ity and non-fatal ischaemic events. Although the no revascularization
subgroup of the present PLATO substudy seems similar to the
TRILOGY-ACS population, it is impossible to compare the effect
of the respective new P2Y12 inhibitor vs. clopidogrel across the
two studies. Patients with intention for treatment without revascu-
larization were prospectively studied in TRILOGY-ACS, while the
present PLATO substudy was a post hoc stratification with subgroups
of revascularization/no revascularization defined post randomization
and post procedures. The TRILOGY-ACS population also was of
higher risk with more prevalent comorbidities such as hypertension,
dyslipidaemia, and diabetes, and had higher rates of previous myocar-
dial infarction and revascularization procedures.
In ACS patients managed with revascularization, more potent
P2Y12 inhibition has been associated with better outcomes, as
shown in the intention for invasive management subgroup analysis
of PLATO for ticagrelor17 and in TRITON for prasugrel.7 In the Clo-
pidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent
Events–Seventh Organization to Assess Strategies in Ischemic
Syndromes (CURRENT OASIS-7) trial also, intensified P2Y12
inhibition with double dose clopidogrel for the first 7 days showed
no significant difference in outcome in the overall population,18
but a reduction in cardiovascular events, including stent thrombosis
in the pre-specified (albeit post-randomization) subgroup under-
going PCI.19
Figure 2 Efficacy endpoints stratified by management strategy—Kaplan–Meier estimates of time to first occurrence of: (A) primary endpoint,
(B) all-cause death, from 10 days post-randomization onward.
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Table 3 Interaction of ticagrelor treatment and revascularization within 10 days (adjusting for region)
NSTE-ACS with revascularization NSTE-ACS without revascularization Interaction
P
N Ticagrelor
KM rate
Clopidogrel
KM rate
HR (95% CI) N Ticagrelor
KM rate
Clopidogrel
KM rate
HR (95% CI)
Efficacy endpoints
CV death/MI
(excluding silent)/
stroke
5416 5.11 6.10 0.86 (0.68, 1.09) 5189 9.63 11.60 0.85 (0.72, 1.01) 0.93
All-cause death/MI
(excl. silent)/
stroke
5416 5.44 6.60 0.85 (0.67, 1.06) 5189 10.15 12.53 0.84 (0.71, 0.99) 0.94
CV death/MI (all)/
stroke/severe
recurrent
ischaemia/
recurrent
ischaemia/TIA/
arterial
thrombotic
event
5290 8.73 10.31 0.86 (0.71, 1.03) 5109 14.14 15.16 0.97 (0.84, 1.13) 0.29
Myocardial
infarction
(excluding silent)
5438 3.52 3.88 0.90 (0.68, 1.21) 5201 6.04 6.68 0.94 (0.75, 1.17) 0.85
Cardiovascular
death (includes
vascular and
unknown deaths)
5648 1.64 2.33 0.76 (0.52, 1.13) 5217 4.07 5.44 0.75 (0.58, 0.98) 0.95
Stroke 5632 0.67 0.59 1.18 (0.60, 2.34) 5209 1.48 1.69 0.92 (0.58, 1.46) 0.56
All-cause death 5648 2.03 2.88 0.75 (0.53, 1.07) 5217 4.77 6.65 0.73 (0.57, 0.93) 0.89
Safety endpoints
Major bleeding
(study criteria)
4983 5.25 4.68 1.10 (0.84, 1.44) 4931 11.83 11.43 1.05 (0.88, 1.26) 0.82
Major or minor
bleeding
(study criteria)
4842 7.76 6.35 1.22 (0.97, 1.54) 4847 14.59 13.96 1.07 (0.91, 1.25) 0.34
Non-CABG major
bleeding
(study criteria)
5270 3.14 2.38 1.32 (0.92, 1.90) 4933 2.78 2.79 1.07 (0.74, 1.56) 0.43
Fatal or
life-threatening
major bleeding
(study criteria)
5173 2.25 2.01 1.18 (0.79, 1.76) 4962 5.77 6.11 0.95 (0.75, 1.22) 0.37
Other major
bleeding
(study criteria)
5178 3.10 2.85 1.02 (0.72, 1.45) 4945 6.50 5.68 1.16 (0.91, 1.49) 0.55
Major bleeding
(TIMI criteria)
5102 3.42 2.79 1.21 (0.86, 1.70) 4952 8.04 8.39 0.97 (0.79, 1.20) 0.28
Major or minor
bleeding
(TIMI criteria)
4990 5.24 4.56 1.12 (0.85, 1.47) 4933 11.78 11.16 1.08 (0.91, 1.29) 0.85
Non-CABG major
bleeding
(TIMI criteria)
5316 1.88 1.19 1.66 (1.01, 2.72) 4952 2.05 1.84 1.19 (0.76, 1.87) 0.34
GUSTO severe
bleeding
5286 1.16 1.49 0.75 (0.45, 1.26) 4946 2.75 2.46 1.13 (0.77, 1.65) 0.22
GUSTO moderate
or severe
bleeding
5134 3.93 3.30 1.13 (0.82, 1.55) 4945 7.18 5.96 1.19 (0.95, 1.51) 0.78
Kaplan–Meier (KM) rates 350 days after day 10 post-randomization.
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With more potent platelet inhibition, bleeding complications have
usually been increasing. In TRITON-TIMI 38, where prasugrel vs. clo-
pidogrel was evaluated in ACS, prasugrel demonstrated a reduction
in thrombotic events, but at the cost of significantly increased rates
of major bleeding, including fatal bleeding, particularly in patients at
high bleeding risk defined as high age and low body weight.7 In
TRILOGY-ACS on the other hand, which included a lower mainten-
ance dose, prasugrel did not cause any increased major bleeding rate,
including patients.75 years of age. In the present analysis, there was
no significant difference in PLATO-defined total major bleeding with
ticagrelor compared with clopidogrel. However, the incidence of
non-CABG-relatedmajor bleeding was significantly higher in the tica-
grelor group. There was no significant difference in life-threatening
or fatal bleeding or major bleeding as defined by the TIMI criteria,
but the composite of PLATO major/minor bleeding was increased
with ticagrelor.
Study limitations
There are several limitations to this work. The sample size is large,
which gives high power to detect even relatively small differences
in effect that may or may not be clinically important. The revascular-
ization/no revascularization analyses were post hoc investigations of
subgroups identified post-randomization, which makes the analyses
subject to potential bias. Because landmark analyses were used, the
risk of time-dependent confounding is acknowledged. As sensitivity
analyses, we also performed landmark analyses at 30 days instead
of 10 days, with consistent results. Nevertheless, the findings
reported with regard to revascularization status should be
Figure3 Bleeding stratified by revascularization—Kaplan–Meier estimate of (A) time to major bleeding according to the PLATO criteria fromday
10 post-randomization, and (B) time to non-CABG major bleeding.
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interpreted strictly as exploratory and hypothesis generating. The
present results based on actual revascularization strategy support
and complement those of our previous analysis based on pre-
randomization intention to treat with invasive or conservative man-
agement, and the results based on performed revascularization or
not are consistent with the overall NSTE-ACS results, as well as
the overall PLATO results.
Conclusions
In this substudy of the PLATO trial, ticagrelor compared with clopi-
dogrel consistently reduced the ratesof ischaemicevents and mortal-
ity without any difference in overall major bleeding in patients with an
entry diagnosis of NSTE-ACS, and this effect was independent of
whether or not early revascularization was performed. These
results harmonize with the European Society of Cardiology (ESC)
NSTE-ACS guidelines, which recommend ticagrelor in all patients
at moderate-to-high risk of ischaemic events, regardless of initial
treatment strategy.1
Supplementary material
Supplementary material is available at European Heart Journal online.
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